- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02941848
Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers
A Randomized, Open-Label, Two-way Crossover, Single-Dose Study to Compare Pharmacokinetic Properties and Safety After Administration of HCP1306 Tablet and Co-administration of HGP0816 Tablet, HGP1404 Tablet in the Healthy Adults
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
[Inclusion criteria]
- Healthy adult of 19 to 50 of age at screening.
18.5 ≤ Body mass index (BMI) < 25.
※ BMS (kg/m2)= body weight (kg)/[height (m)2]
- Body weight ≥ 55 kg for men and ≥ 50 kg for women.
- Individual considered by the responsible physician to be eligible as a subject based on the results of hematology test, blood chemistry test, immunoserology test, urinalysis, and electrocardiogram (ECG) as performed according to the characteristics of the drug (including those with not clinically significant (NCS) abnormalities).
Women must have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test at screening and a negative pre-dose urine β-hCG test at a time point defined in the protocol and must be applicable to one of the followings.
- Postmenopausal (no spontaneous menstruation for at least 2 years)
- Surgical sterilization (sterilized by hysterectomy, bilateral ovariectomy or tubal ligation, or other methods)
- A male partner is sterilized prior to screening (documented azoospermia following vasectomy) and this man is the subject's only partner.
The subject must agree to use adequate methods of contraception continuously and properly during the period of time from at least 14 days prior to the first dose to at least 28 days after the last dose of the investigational product.
- Adequate methods of contraception include abstinence and physical barrier methods (e.g., condom, diaphragm, or cervical cap) and contraceptive devices or pills containing hormones that may have drug-drug interactions with the investigational product are not to be used during the study period, in principle.
- Sexually active male subject with a female partner of childbearing potential must agree to avoid pregnancy (condom, etc.) during the study and to maintain adequate methods of contraception and not donate sperms during the study and for 28 days after the last dose of the investigational product (the methods of contraception are not necessary if the male subject or his female partner is sterile).
- After receiving and understanding sufficient explanations about the study, the individual must voluntarily decide to participate in the study and provide written informed consent to complying with study instructions.
[Exclusion criteria]
- Evidence or history of clinically significant diseases in the hepatobiliary system, kidney, nervous system, psychiatric system, respiratory system, endocrine system (thyroid dysfunction, etc.), hemato-oncology, cardiovascular system, immune system, or musculoskeletal system (myopathy, etc.).
- History of gastrointestinal disorders (e.g., Crohn's disease, ulcerative colitis) or surgery (except for simple typhlotomy or hernia repair) that may affect the absorption of the investigational product.
- Hypersensitivity reactions to any of the components of the investigational product or its excipients or drugs of the same class.
- Hereditary disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
- Vital signs measured in the sitting position after at least 5 minutes of rest as follows: systolic blood pressure (SBP) > 150 mmHg or < 90 mmHg or diastolic blood pressure (DBP) > 100 mmHg or < 50 mmHg.
Screening clinical laboratory test results as follows:
- Blood total bilirubin level > 1.5 x upper limit of normal (ULN)
- Blood aspartate aminotransferase (AST, also known as serum glutamic oxaloacetic transaminase [SGOT]) or alanine aminotransferase (ALT, also known as serum glutamate pyruvate transaminase [SGPT]) > 1.25 x ULN
- Blood urea nitrogen (BUN) > 25.0 mg/dL or creatinine > 1.4 mg/dL
Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 as calculated by the Modification of Diet in Renal Disease (MDRD) equation
※ eGFR (mL/min/1.73m2) = 175 x [serum creatinine (mg/dL)]-1.154 x [age (years)]-0.203 (X 0.742, if female)
- Blood Creatinine Phosphokinase (CK) > 2 x ULN
- History of significant drug abuse within 1 year of screening or positive urine drug test results.
- Administration of drugs within 30 days of the investigational product administration that are expected to or may affect the metabolism of the investigational product.
Administration of the following drugs within the relevant period, except for local agents without significant systemic absorption and hormonal contraceptives.
- Ethical (ETC) drugs within 14 days of the first investigational product administration
- Over-the-counter (OTC) drugs including health foods and vitamin preparations within 7 days of the first investigational product administration
- Drugs administered via depot injection or other implantations (except for contraceptives) within 30 days of the first investigational product administration
- Significant alcohol dependency within 1 year of screening, continuous drinking within 6 months of screening (> 210 g/week), or unable to refrain from drinking during the study period starting from 2 days prior to the first investigational product administration.
- Continuous caffeine intake (e.g., coffee > 5 cups/day, tea > 1250 cc/day, cola > 1250 cc/day) or unable to refrain from caffeine intake during the study period starting from 2 days prior to the first investigational product administration.
- Continuous smoking (> 10 cigarettes/day) or unable to refrain from smoking during the study period starting from 2 days prior to the first investigational product administration.
- Intake of grapefruits or foods containing grapefruits within 7 days prior to the first investigational product administration.
- Participation in another clinical trial (including a bioequivalence study) and administration of another investigational product within 60 days prior to the investigational product administration in this study (3 months for biologics; a prolonged period of time may be applied with half life taken into account).
- Whole blood donation within 60 days or apheresis donation within 30 days prior to the investigational product administration.
- Pregnant or lactating women.
- Subject considered by the investigator to be inappropriate for study participation due to other reasons.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Group1
C → A + B A : HGP0816 B : HGP1404 C : HCP1306 |
|
Expérimental: Group2
A + B → C A : HGP0816 B : HGP1404 C : HCP1306 |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
AUClast of Rosuvastatin
Délai: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Cmax of Rosuvastatin
Délai: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
AUClast of Free Ezetimibe
Délai: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Cmax of Free Ezetimibe
Délai: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
AUCinf of Rosuvastatin
Délai: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
tmax of Rosuvastatin
Délai: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
t1/2 of Rosuvastatin
Délai: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
CL/F of Rosuvastatin
Délai: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Vd/F of Rosuvastatin
Délai: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
MRT of Rosuvastatin
Délai: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
AUCinf of Free Ezetimibe
Délai: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Tmax of Free Ezetimibe
Délai: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
T1/2 of Free Ezetimibe
Délai: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
CL/F of Free Ezetimibe
Délai: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Vd/F of Free Ezetimibe
Délai: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
MRT of Free Ezetimibe
Délai: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Choon Ok Kim, MD, Yonsei University Health system, Severance Hospital
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- HM-ROZE-102
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur HGP0816
-
Hanmi Pharmaceutical Company LimitedComplétéEn bonne santéCorée, République de
-
Hanmi Pharmaceutical Company LimitedComplétéHypertension | HyperlipidémieCorée, République de
-
Hanmi Pharmaceutical Company LimitedComplétéHypercholestérolémie primaireCorée, République de
-
Hanmi Pharmaceutical Company LimitedInconnue